ImmunoBiochem Corporation

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
ImmunoBiochem is an immuno-oncology biopharmaceutical company that has developed a disruptive approach to targeting unique proteins amplified in cancer secretomes. These targets are secreted from cancer cells and accumulate in tumors, but not in normal tissues, and are constantly recycled in the tumor microenvironment. This novel approach enables the selective and efficacious delivery of immunomodulatory and chemotherapeutic payloads into relevant subsets of cells within the tumor microenvironment, including tumor cells, immune cells and tumor-supporting stroma.
ImmunoBiochem’s IMB-213I candidate delivers a potent innate immune system agonist for the treatment of highly heterogeneous solid tumors, such as TNBC, pancreatic and ovarian cancers.
ImmunoBiochem's IMB-212 candidate delivers a potent cytotoxic payload into difficult-to-treat solid tumors, particularly where no suitable surface targets and no biologics are available.
Company Type:
Company Website:
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
IMB-213I - immunomodulatory antibody conjugate for the treatment of solid tumors
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
Director & CEO
ImmunoBiochem Corporation